We recognize the importance of cash efficiency and we are disciplined in how we deploy our cash resources, making sure we will focus on reaching key milestones with our available cash runway at least through the end of 2024. It is important to emphasize that this does not include any potential cash inflows, including potential milestones payment from our collaborator AstraZeneca. Expenses for the first quarter of 2023 were in line with our plans. R&D expenses for the first quarter of 2023 were $7.4 million, ...

Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Yvonne Naughton - Head, IR and Corporate Communications Anat Cohen-Dayag - President and CEO Henry Adewoye - Chief Medical Officer Eran Ophir - SVP, Research and Drug Discovery Alberto Sessa - CFO Conference Call Participants Stephen Willey - Stifel Mark Breidenbach - Oppenheimer Asthika Goonewardene - Truist Securities Daina Graybosch - SVB Securities Charles Butler - EF Hutton Operator Ladies and ...

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definitio ...

om pugen FROM CODE TO CURE® Corporate Overview 14 November 2022 מפככפכדתכרכוכ DOCTCTCTCTCCC Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," ...

Compugen Ltd. (NASDAQ:CGEN) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Yvonne Naughton - Head, Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Henry Adewoye - Chief Medical Officer Eran Ophir - Senior Vice President, Research and Drug Discovery Alberto Sessa - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Mark Breidenbach - Oppenheimer Reni Benjamin - JMP Securities Daina Graybosch ...

Compugen Ltd. (NASDAQ:CGEN) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Yvonne Naughton - Head of IR and Corporate Communications Anat Cohen-Dayag - President & CEO Ari Krashin - Chief Financial & Operating Officer Henry Adewoye - Chief Medical Officer Eran Ophir - Vice President Research & Drug Discovery Conference Call Participants Bonnie Quach - Stifel Mark Breidenbach - Oppenheimer Tony Butler - Roth Capital Daina Graybosch - SVB Leerink Reni Benjamin - JMP Securities ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________ FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15( ...

Compugen Ltd. (NASDAQ:CGEN) Q4 2021 Results Conference Call February 24, 2022 8:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO Yvonne Naughton - Head of Investor Relations and Corporate Communications Henry Adewoye - Chief Medical Officer Ari Krashin - Chief Financial and Operating Officer Eran Ophir - Vice President Research & Drug Discovery Conference Call Participants Stephen Willey - Stifel Reni Benjamin - JMP Securities Tony Butler - ROTH Capital Daina Graybosch - SVB Leerink Operat ...

Compugen Ltd. (NASDAQ:CGEN) Q3 2021 Earnings Conference Call November 12, 2021 ET Company Participants Anat Cohen-Dayag – President and CEO Yvonne Naughton – Head of Investor Relations and Corporate Communications Henry Adewoye – Chief Medical Officer Ari Krashin – Chief Financial and Operating Officer Eran Ophir – Vice President Research & Drug Discovery Conference Call Participants Mark Breidenbach – Oppenheimer Stephen Willey – Stifel Daina Graybosch – SVB Chris Howerton – Jefferies Tony Butler – ROTH Ca ...

Financial Data and Key Metrics Changes - Research and development expenses for Q2 2021 were $6.8 million, an increase from $4.4 million in Q2 2020, reflecting the expansion of clinical trials [41] - Net loss for Q2 2021 was $9.5 million or $0.11 per share, compared to a net loss of $6.2 million or $0.08 per share in Q2 2020 [42] - As of June 30, 2021, the company had approximately $111 million in cash, down from approximately $119 million as of March 31, 2021, with no debt [42] Business Line Data and Key Metrics Changes - The company is focused on the DNAM axis, specifically targeting PVRIG, TIGIT, and PD-1 pathways, with ongoing clinical studies evaluating these pathways [6][11] - COM701, the first-in-class anti-PVRIG antibody, is being evaluated in monotherapy and combination studies, showing promising preliminary data [12][14] - COM701 in combination with nivolumab resulted in a disease control rate of 67%, with notable responses in tumor types typically unresponsive to immune checkpoint inhibitors [13] Market Data and Key Metrics Changes - The company is the only one targeting PVRIG in a clinical setting, maintaining a first-mover advantage in the DNAM axis [11][28] - There is growing interest in the dual and triple blockade of DNAM axis members, indicating a competitive landscape in immuno-oncology [28][29] Company Strategy and Development Direction - The company aims to maintain its first-mover advantage by executing a comprehensive clinical program with innovative combination therapies [17][34] - The strategy includes a biomarker-informed clinical program to evaluate different combinations of PVRIG, TIGIT, and PD-1 across various tumor types [10][21] - The company is considering adding inflamed indications to its studies to assess the full blockade of the DNAM axis [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of COM701 and COM902 to expand the reach of immunotherapy to patients unresponsive to current treatments [39] - The company plans to continue executing its clinical strategy with several milestones expected in the second half of 2021, including data from ongoing studies [32][34] Other Important Information - The company has a collaboration with Bayer for the development of ILDR2, with enrollment accelerating in the Phase 1 cohort expansion study [37][38] - The company is actively pursuing biomarker identification to correlate expression levels with clinical responses [22][66] Q&A Session Summary Question: What is the potential of TCF7 as a biomarker for patients? - Management indicated that TCF7 may be a challenging biomarker to monitor from peripheral blood compared to tumor samples [44][46] Question: What are the expected patient numbers for upcoming readouts? - Approximately 15 to 20 patients are expected for both the triple combination and COM902 dose escalation studies [49] Question: How does the company view the activity of VISTA in relation to the DNAM axis? - Management acknowledged the importance of MIALU checkpoints and is evaluating their efficacy in combination with current pipelines [51][53] Question: What is the company's strategy regarding potential partnerships? - The company is open to collaborative arrangements while ensuring it retains control over its key assets [60][61] Question: What is the correlation between PVRL2 and PD-L1 expression? - PVRL2 can be high in both PD-L1 positive and negative tumor types, indicating its potential as a target in various cancers [92] Question: Is there a correlation between peripheral and intratumoral immune cell populations? - There is a correlation, but the company emphasizes the importance of tumor biopsies for accurate assessment [93][94]